cellArtgen
- Company typePrivate
- Founded2020
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What cellArtgen does
CellArtgen (주식회사 세라트젠) is a Seoul-based regenerative medicine biotechnology company founded in 2020 as a spin-off from Yonsei University, specializing in the convergence of organoid technology and functional biomaterials. The company develops three core technology platforms: organoid culture and manufacturing technology, organoid advancement/analytical technology (including molecular, electrical, structural, imaging, and AI-based analysis), and engraftable biomaterial technology. Its commercial portfolio centers on the Regenix® platform — decellularized organoid culture materials available across nine organ types (liver, intestine, lung, heart, kidney, uterus, muscle, skin, and xenograft) — and ORGANOSCREEN, a preclinical drug evaluation service using organoid-based disease models for conditions including MASH (liver), IPF (lung), sarcopenia (muscle), and cardiac safety assessment. CellArtgen claims to be Korea's first provider of liver organoid-based MASH and lung organoid-based IPF drug evaluation services.
The company operates a horizontally diversified business model across B2B pharmaceutical services, B2B research product sales, and consumer aesthetics. Revenue is generated through four streams: (1) ORGANOSCREEN preclinical evaluation services sold to domestic and global pharmaceutical companies and CROs, (2) Regenix product sales to research institutions, (3) medical biomaterial products co-developed with partners such as MonetCell for tissue regeneration, and (4) Cellumé, an ECM-based dermocosmetic skincare brand distributed through GS Home Shopping and live commerce channels (including Japan TikTok Shop). The organization has 11-50 employees, holds approximately 90+ domestic and international patents, and reports GMP certification obtained in January 2026 for wound coverage materials. Key academic partnerships include Yonsei University, Sungkyunkwan University, iPS Academia Japan, and the Korea Brain Research Institute, with strategic biotech collaborations including ToolGen, Kangstem, Mepsgen, and Woongbi Meditech.
cellArtgen firmographics
Firmographics- Name
- cellArtgen
- Legal name
- 주식회사 세라트젠
- Website
- https://cellartgen.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
cellArtgen industry classification
Industry- Product category
- Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industries
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)
Keywords
Where cellArtgen is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
cellArtgen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Drug Evaluation Services (ORGANOSCREEN): Preclinical evaluation services using organoid-based disease models for pharmaceutical companies. Services include efficacy and safety assessment for drug candidates using liver, lung, muscle, and heart organoids.
- Regenix Product Sales: Sale of cell culture materials branded as Regenix for various organoid types (Liver, Intestine, Lung, Heart, Kidney, Uterus, Muscle, Skin, Xenograft).
- Biomaterial Products: Medical biomaterials including decellularized ECM products for tissue regeneration and aesthetic applications.
- Cellumed Skincare: ECM-based skincare products (Cellumed brand) sold through GS Home Shopping and live commerce channels.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Regenix product catalog with various organoid types |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
cellArtgen product offering
Product offeringCore offering
CellArtgen develops and sells organoid-based disease modeling platforms and functional biomaterials for regenerative medicine. Its core offerings include the Regenix decellularized organoid culture material platform covering multiple organ types (liver, lung, heart, intestine, kidney, uterus, muscle, skin, and xenograft) and the ORGANOSCREEN preclinical drug evaluation service that uses organoid disease models for efficacy and safety assessment. The company also extends its ECM biomaterial technology into the consumer skincare market through its Cellumé brand.
Product overview
CellArtgen (CELLARTGEN, CELLARTGEN Inc.) is a regenerative medicine biotech offering a portfolio of products and services centered on its organoid culture technology platform and biomaterial technologies. The core offering is the Regenix® platform, a line of decellularized organoid culture materials branded for specific organ types (Liver, Intestine, Lung, Heart, Kidney, Uterus, Muscle, Skin) available in pre-gel solution and powder forms. Alongside the Regenix® product line, the company provides ORGANOSCREEN, a preclinical drug evaluation service using organoid-based disease models for efficacy and safety assessment. A consumer-facing derma-cosmetic sub-brand, Cellumé (쎌루메), extends the ECM biomaterial technology into the aesthetic skincare market. Regenix® Xenograft supports allogeneic cancer transplantation research.
Differentiator
Problem solved
Functional benefit
Brands
- Cellumé (쎌루메): ECM-based dermocosmetic skincare product line launched by CellArtgen, targeting the aesthetic and skin beauty market.
- Regenix®
- ORGANOSCREEN (오가노스크린)
Products and services
- Regenix
- ORGANOSCREEN
- Cellumé
Quantifiable outcome
- Published in Nature Reviews Bioengineering (Impact Factor 37.1)
- +4 more outcomes
Companies that use cellArtgen
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
cellArtgen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
cellArtgen partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered minor and core.
- 오송첨단의료산업진흥재단 (Osong Medical Industry Promotion Foundation)minorGMP certification support through Open-Factory facilities including cleanroom, manufacturing space, and quality control support.
- 성균관대학교 (Sungkyunkwan University)coreLead institution for Ministry of Science and ICT's brain organoid commercialization core technology development project (₩142 billion over 7 years).
- 넥스트앤바이오, 센트럴바이오 (Next&Bio, CentralBio)minorCollaborating partners in brain organoid commercialization project for dementia and Parkinson's precision medicine platform.
- 연세대학교 (Yonsei University)coreResearch affiliation with Yonsei University Life Biotechnology department where CEO Professor Seung Woo Cho serves. Primary research partner for organoid technology development.
- 모닛셀 (MonitCell)coreStrategic MOU for developing medical biomaterials based on human adipose ECM. Aims to enter beauty, plastic surgery, and advanced regenerative medicine markets.
- iPS Academia JapancoreCommercial license agreement for iPSC-derived organoid manufacturing technology commercialization. iPS Academia Japan manages Shinya Yamanaka's Nobel-winning technology licenses.
- 충청도 (Chungbuk Province)minorBusiness agreement for global organoid regenerative medicine activation with 14 institutions including provincial government, hospitals, and biotech companies.
- 강스템 (Kangstem)minorMOU for diabetes organoid treatment drug development collaboration.
- 웅비메디텍 (Woongbi Meditech)minorJoint marketing agreement for organoid culture materials.
- 멥스젠 (Mepsgen)minorCollaboration for human tissue chip platform development.
- 툴젠 (ToolGen)coreJoint R&D agreement for gene-corrected stem cell development combining ToolGen's CREAM technology with CellArtGen's functional hydrogel for ischemic disease treatment.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
cellArtgen competitors and assessment
Company assessmentDirect peers
- Emulate Inc. US-based organ-on-chip and microphysiological systems company providing in vitro disease models for preclinical drug evaluation. Directly comparable to CellArtgen's ORGANOSCREEN platform, with both targeting pharma preclinical services using human-relevant 3D cellular models.
- InSphero: Swiss 3D organoid and microtissue company providing disease models and preclinical services for pharmaceutical R&D. Directly comparable to CellArtgen's multi-organ organoid product line (liver, lung, heart, etc.) and B2B pharma service model.
- Stemcell Technologies: Canadian supplier of cell culture media, reagents, and organoid tools for life science research. Comparable as a research product catalog player in the organoid ecosystem, with similar B2B distribution model to CellArtgen's Regenix catalog.
- Crown Bioscience: Global preclinical CRO with significant organoid and PDX services for oncology and metabolic disease. Direct competitor in organoid-based preclinical drug evaluation, especially relevant as CellArtgen pursues global CRO partnerships for international market access.
- CN Bio: UK organ-on-chip and microphysiological systems company offering single- and multi-organ chips for drug discovery and preclinical testing. CellArtgen partners with Mepsgen (human tissue chip platform), making CN Bio a closely adjacent comparable in human-relevant preclinical platforms.
- Hesperos Inc. US-based microphysiological systems company using organ-on-chip technology for preclinical drug testing, particularly in neuromuscular and rare disease. Comparable to CellArtgen's muscle organoid and cardiac organoid services within ORGANOSCREEN.
Broad incumbents
- WuXi AppTec: China-based global CRO/CDMO with extensive preclinical, cell therapy, and organoid-related services. Comparable broad incumbent serving pharma preclinical evaluation, particularly relevant given Asian market overlap.
- Charles River Laboratories: Global preclinical CRO with broad services including emerging organoid and in vitro capabilities. Represents the broader incumbent landscape CellArtgen competes against for pharma preclinical outsourcing contracts.
Emerging players
- Organovo Holdings: US-based 3D bioprinting and tissue engineering company focused on therapeutic tissues and preclinical disease models. Comparable adjacent player in regenerative medicine and tissue engineering technology platforms.
Regional players
- Medipost: Korean stem cell therapy company (Cartistem, Neurostem) operating in regenerative medicine. Comparable Korean regional peer in cell-based therapeutics with similar regulatory and market positioning for advanced therapy products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
cellArtgen social profiles
Digital presencecellArtgen compliance and trust
Trust signalCompliance1 record
cellArtgen financial estimates
Financial estimateRevenue estimate
Valuation estimate
cellArtgen leadership team
Management profileNumber of profiles
Profiles3 records
cellArtgen funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
cellArtgen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about cellArtgen
What does cellArtgen do?
CellArtgen develops and sells organoid-based disease modeling platforms and functional biomaterials for regenerative medicine. Its core offerings include the Regenix decellularized organoid culture material platform covering multiple organ types (liver, lung, heart, intestine, kidney, uterus, muscle, skin, and xenograft) and the ORGANOSCREEN preclinical drug evaluation service that uses organoid disease models for efficacy and safety assessment. The company also extends its ECM biomaterial technology into the consumer skincare market through its Cellumé brand.
Is cellArtgen a public or private company?
cellArtgen is a private company. It is classified as venture growth investor backed and is currently operating.
When was cellArtgen founded?
cellArtgen was founded in 2020. It employs 11 to 50 people.
Where is cellArtgen based?
cellArtgen is headquartered in Seoul, South Korea, in the Asia region.
How does cellArtgen make money?
Four revenue lines are on record. Drug Evaluation Services (ORGANOSCREEN) is the primary driver. The others are regenix Product Sales, biomaterial Products and cellumed Skincare.
Who are cellArtgen's main competitors?
Direct peers on record are Emulate Inc., InSphero, Stemcell Technologies, Crown Bioscience, CN Bio and Hesperos Inc.. Broad incumbents are WuXi AppTec and Charles River Laboratories. Organovo Holdings is listed as an emerging player. Medipost is listed as a regional player.
Does cellArtgen have an API?
No public API is recorded for cellArtgen.
What industry is cellArtgen in?
cellArtgen's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 325414 and its SIC code is 2836.